Augmenting chemosensitivity of malignant melanoma tumors via proteasome inhibition: Implication for bortezomib (VELCADE, PS-341) as a therapeutic agent for malignant melanoma

Kalayoun I. Amiri, Linda W. Horton, Bonnie J. LaFleur, Jeffrey A. Sosman, Ann Richmond

Research output: Contribution to journalArticlepeer-review

145 Scopus citations

Fingerprint

Dive into the research topics of 'Augmenting chemosensitivity of malignant melanoma tumors via proteasome inhibition: Implication for bortezomib (VELCADE, PS-341) as a therapeutic agent for malignant melanoma'. Together they form a unique fingerprint.

Medicine & Life Sciences